Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Fulvestrant in AI-Resistant Breast Cancer
NCT00570921Phase 2Completed
- Sponsor
- MARAbio Systems
- Start
- Apr 2008
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Hormone-Receptor-Positive Breast Cancer, breast cancer, sponsored by MARAbio Systems. Started Apr 2008; status: completed.
02
Drugs
everolimus
03
Conditions
Hormone-Receptor-Positive Breast Cancerbreast cancer
Beyond the preview
Go deeper on NCT00570921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570921.